BridgeMD
New treatment option for Functional Dyspepsia
Official title Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
ClinicalTrials.gov ID: NCT06756139
What this study is testing
What is Flupentixol and Melitracen Tablets?
Flupentixol and Melitracen Tablets is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for functional dyspepsia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost. Antipsychotic drugs were demonstrated to be effective in relieving symptoms in FD patients, especially for patients with refractory FD.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age 18-80
- Refractory functional dyspepsia (patients with Rome IV functional dyspepsia remained symptomatic after treatment of 8 weeks of proton pump inhibitor...
- Negative or unrelated-to-FD symptom findings of gastroscopy, upper abdominal ultrasound, Hp test and routine blood tests within the past 1 year.
You likely can't join if
- Severe mental illness (PHQ-9 ≥20 or GAD-7 ≥15) or suicidal ideation;
- Known hp infection, active gastrointestinal peptic ulcer, cholecystitis, gallstones, suspected or known bowel obstruction, gastroparesis, major...
- Known or suspected malignant tumor, significant heart/brain/liver/kidney diseases, obvious hematologic abnormalities or endocrine diseases etc...
- Known or suspected drug-related FD (e.g.NSAIDs-related FD);
- Unable to access to mobile networks or unable to manage mobile APP properly.
- Allergy or other contradictions to flupenthixol or melitracen
See the full eligibility criteria
- Age 18-80
- Refractory functional dyspepsia (patients with Rome IV functional dyspepsia remained symptomatic after treatment of 8 weeks of proton pump inhibitor and 4 weeks of prokinetics)
- Negative or unrelated-to-FD symptom findings of gastroscopy, upper abdominal ultrasound, Hp test and routine blood tests within the past 1 year.
- Severe mental illness (PHQ-9 ≥20 or GAD-7 ≥15) or suicidal ideation;
- Known hp infection, active gastrointestinal peptic ulcer, cholecystitis, gallstones, suspected or known bowel obstruction, gastroparesis, major gastrointestinal surgery etc.;
- Known or suspected malignant tumor, significant heart/brain/liver/kidney diseases, obvious hematologic abnormalities or endocrine diseases etc., which may be -related to FD symptoms;
- Known or suspected drug-related FD (e.g.NSAIDs-related FD);
- Unable to access to mobile networks or unable to manage mobile APP properly.
- Allergy or other contradictions to flupenthixol or melitracen
- Taking any antipsychotics drugs or CBT interference within 12 weeks
- Pregnant or lactating women;
- Unable to provide informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Haikou, Hainan, China
- Xi'an, Shaanxi, China
- Mianyang, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Haikou, Hainan, China; Xi'an, Shaanxi, China; Mianyang, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.